BC Week In Review | Apr 15, 2013
Clinical News

Interneuron regulatory update

IPIC submitted an NDA to the FDA for CerAxon citicoline to treat ischemic stroke. The NDA is based on Phase III results announced last summer (see BioCentury Extra, July 16). Interneuron Pharmaceuticals Inc. (IPIC), Lexington,...
BioCentury | Oct 30, 2006
Product Development

Trail of tearst

Trail of tearst Company Product Product description Setback Anti-platelet & anti-inflammatory agents Eli Lilly/J&J ReoPro abciximab MAb against GPIIb/IIIa (CD41/CD61) and integrin alpha(5)beta(3) In 2005, stopped development in ischemic stroke after discontinuing enrollment in a...
BC Week In Review | Nov 1, 2004
Company News

Ivax, Ferrer deal

IVAX and Grupo Ferrer partnered to develop citicoline, an oral neuroprotective therapy to treat stroke. Under the deal, IVAX will be responsible for regulatory approval in the U.S. The compound is marketed in 70 countries...
BioCentury | Apr 3, 2000
Finance

Better than it felt

The quarter ended on a positive note, with the FDA granting approval to Zonegran zonisamide anti-convulsant capsules from Elan Corp. plc (ELN) as an adjunctive therapy to treat partial seizures in adults with epilepsy, and...
BC Week In Review | Jan 17, 2000
Clinical News

CerAxon citicoline: Phase III

Preliminary analysis of IPIC's 899-patient Phase III ECCO 2000 trial showed that CerAxon citicoline failed to meet its primary end point of improved neurological function from baseline compared to placebo as measured by the National...
BioCentury | Jan 17, 2000
Finance

Interneuron Pharmaceuticals (IPIC)

Interneuron Pharmaceuticals (IPIC) Market value tracking: Interneuron Pharmaceuticals (IPIC) Interneuron (IPIC) plummeted $4.125 (59 percent) to $2.813 on Monday when the company reported that preliminary analysis of its Phase III ECCO 2000 trial showed that...
BioCentury | Jan 4, 2000
Strategy

Interneuron: Rehabilitation

Through a flurry of deals at year end, Interneuron Pharmaceuticals Inc. is working to rehabilitate its original business model of in-licensing products, adding value through clinical trials and regulatory milestones and then out-licensing the products...
BioCentury | Dec 6, 1999
Strategy

Abgenix's beachhead

The combination of Abgenix Inc. 's XenoMouse technology to generate human antibodies with Human Genome Sciences Inc. 's secreted protein target antigens illustrates the potential for exploiting genomics with a rapid product development cycle. HGSI...
BC Week In Review | Aug 30, 1999
Clinical News

CerAxon citicoline: Completed Phase III trial enrollment

Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass.   Product: CerAxon citicoline   Business: Neurological   Therapeutic category: Neurotransmission   Target: Neurotransmitters   Description: Booster of acetylcholine and other neural components   Indication: Treat ischemic stroke  ...
BioCentury | Aug 30, 1999
Finance

The momentum returns

Momentum investors have vigorously returned to the biotech space, and it's becoming clear that their aggregate buying is responsible for several of the monstrous price gains in the big cap (over $1 billion) names. As...
Items per page:
1 - 10 of 40